Drug Type Small molecule drug |
Synonyms Amoprel, 아모프렐정 |
Action antagonists, blockers, inhibitors |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), L-type calcium channel blockers(Voltage-gated L-type calcium channel blockers), NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (30 May 2025), |
Regulation- |
Molecular FormulaC22H23ClKN6O |
InChIKeyFDKIDFYIEWFERB-UHFFFAOYSA-N |
CAS Registry124750-99-8 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Essential Hypertension | South Korea | 30 May 2025 |